Jazz Pharmaceuticals plc (JAZZ) Stock Overview
Explore Jazz Pharmaceuticals plc’s financial performance, market position, analyst ratings, and future outlook.
Jazz Pharmaceuticals plc (JAZZ)
Key Financials
Key Financials
Market Cap
14.4B
P/E Ratio
482.72
EPS (TTM)
$0.12
ROE
0.01%
JAZZ Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Jazz Pharmaceuticals plc (JAZZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 51.71, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $152.31.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 482.72 and a market capitalization of 14.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.